FAIRFIELD, N.J., Jan. 10 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc., , announced today that the Company’s Doak Dermatologics subsidiary is the presenting sponsor, providing a major unrestricted educational grant for the Superbones/Superskin(TM) seminar, making the Company the primary financial supporter of this event. Doak provided this grant to the Rhode Island Podiatric Medical Association and the Virginia Foot & Ankle Institute, the organizations who jointly offer this annual seminar and the Continuing Medical Education (CME) credits for this meeting.
Superbones/Superskin(TM), to be held January 12-15, 2006, is emerging as one of the most important podiatric Continuing Medical Education (CME) meetings. For several years, Doak has participated as a major supporter for this seminar. For 2005 Superbones/Superskin(TM), Doak also provided a major unrestricted educational grant. This commitment made Doak the sole primary financial supporter of that event. Approximately 225 Doctors of Podiatric Medicine are registered for this year’s CME workshops on dermatology, diabetes, trauma, wound care and vascular surgery.
Bradley President and CEO, Daniel Glassman, stated, “Bradley’s Doak Dermatologics subsidiary is proud to support podiatric education activity including Superbones/Superskin(TM) seminar, recognizing the significance of podiatry as a medical specialty. An important aspect of podiatry is identifying potentially serious conditions that can manifest throughout the body, often in the lower extremities. As a result of CME seminars such as Superbones/Superskin(TM), many patients may receive necessary, and possibly lifesaving, treatment for conditions that may otherwise have gone unnoticed. Doak is pleased to continue to participate in the advancement of podiatric patient care.”
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry, Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands and A. Aarons which will market authorized generic versions of Doak and Kenwood therapies.
Important announcement:
Daniel Glassman will present at the Raymond James & Associates 27th Annual Institutional Investors Conference, Hyatt Regency Grand Cypress in Orlando, FL, March 5-8th, 2006.
Daniel Glassman will present at the Banc of America Securities LLC, Health Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV, May 16-18th, 2006.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations, Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
Web site: http://www.bradpharm.com/
